Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2016 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications

REHOVOT, Israel, Sept. 29, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
September 22, 2016 16:01 ET | Source: NeuroDerm Ltd.

NeuroDerm’s ND0612 Mini-Pump Delivery System Successfully Used by Parkinson’s Disease Patients in Home Setting

REHOVOT, Israel, Sept. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
September 19, 2016 09:28 ET | Source: NeuroDerm Ltd.

NeuroDerm to Present ND0612 Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System

REHOVOT, Israel, Sept. 19, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
August 25, 2016 07:25 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update

REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
August 25, 2016 07:18 ET | Source: NeuroDerm Ltd.

NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson’s Disease

REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
August 11, 2016 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm to Host Second Quarter 2016 Financial Results Conference Call on August 25, 2016

REHOVOT, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
July 27, 2016 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Issuance of a New U.S. Patent for Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions

REHOVOT, Israel, July 27, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
July 26, 2016 08:07 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Start of Bioequivalence Trial in Healthy Volunteers of ND0701, a New Continuous Subcutaneously Delivered Apomorphine Product Candidate for the Treatment of Advanced Parkinson’s Disease

- ND0701 complements the company’s product pipeline for the treatment of advanced Parkinson's disease - - ND0701's proprietary formulation is designed to improve patient convenience by allowing...
July 06, 2016 11:02 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Additions to Management Team

REHOVOT, Israel, July 06, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced...
July 05, 2016 09:04 ET | Source: NeuroDerm Ltd.

NeuroDerm to Present at the Cantor Fitzgerald Healthcare Conference on July 13

REHOVOT, Israel, July 05, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...